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Abstract
Plasma potassium concentration (PK) is tightly regulated. Insulin is known to
favor potassium entry into cells. But how potassium leaves the cells later on is
not often considered. Previous studies in rats showed that glucagon infusion
increased urinary potassium excretion dose-dependently and reversibly. This
prompted us to investigate the possible influence of glucagon on potassium
handling in humans. We took advantage of the Gly40Ser mutation of the glu-
cagon receptor (GR) that results in a partial loss of function of the GR. In the
Olivetti cohort (male workers), 25 subjects who carried this mutation were
matched 1:4 to 100 noncarriers for age and weight. Estimated osmolarity of
serum and 24-h urine (Sosm and Uosm, respectively) was calculated from the
concentrations of the main solutes: [(Na+K)*2 + urea (+glucose for serum)].
Transtubular potassium gradient (TTKG), reflecting the intensity of K secre-
tion in the distal nephron, was calculated as [(urine K/serum K)(Uosm/Sosm)].
There was no significant difference in serum K, or 24-h urine urea, Na and K
excretion rates. But urine K concentration was significantly lower in carriers
than in noncarriers. Means (interquartile range): 38 (34–43) versus 47 (43–51)
mmol/L, P = 0.030. TTKG was also significantly lower in carriers: 4.2 (3.9–
4.6) versus 5.0 (4.7–5.2), P = 0.015. This difference remained statistically sig-
nificant after adjustments for serum insulin and 24-h Na and urea excretions.
These results in humans suggest that glucagon stimulates K secretion in the
distal nephron. Thus, in conjunction with insulin, glucagon may also partici-
pate in K homeostasis by promoting renal K excretion.
Introduction
The regulation of plasma potassium concentration (PK) is
assumed to depend mainly on aldosterone. However, aldos-
terone has an opposite influence on the excretion rates of
potassium and sodium and thus cannot alone regulate the
plasma level of each of these two cations independently.
Insulin may play an additional role. Insulin release is stim-
ulated after a large oral intake or infusion of potassium,
and this hormone allows potassium entry into cells (mostly
hepatocytes and muscle cells), thus attenuating the rise in
PK. But potassium cannot be stored in these cells
permanently. To our knowledge, how potassium is subse-
quently released by these cells has never been addressed
thus far. Nevertheless, since potassium excretion increases
more rapidly after the ingestion or infusion of a potassium
load than what would be expected from a steroid-depen-
dent mechanism, a few authors have postulated the exis-
tence of an aldosterone-independent kaliuretic factor
(Rabinowitz 1991; Gumz et al. 2015).
During renal clearance studies in rats, we observed that
an i.v. infusion of glucagon induced a marked increase in
urinary potassium excretion that was dose-dependent and
reversible (Ahloulay et al. 1995). This suggested that
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glucagon could facilitate the excretion of potassium by
stimulating potassium secretion in the collecting duct, and
thus could reduce PK and allow the progressive release of
potassium from the cells where it was temporarily stored
under the influence of insulin. As glucagon and insulin play
opposite roles in glucose homeostasis, it is conceivable that
they may also play opposite roles in potassium homeosta-
sis. Several arguments supporting this hypothesis have been
described in a recent review (Bankir et al. 2016).
A polymorphic variant of the glucagon receptor gene has
been described. It is the result of a missense mutation lead-
ing to the substitution of a serine for a glycine in the encoded
protein (Gly40Ser) (Shiota et al. 2002; Barbato et al. 2003).
This variant is present in 1–3% of Caucasian populations.
The receptor protein expressing this variant is less sensitive
to glucagon, as indicated by a lower production of cAMP by
liver cell membranes in vitro (Hager et al. 1995; Hansen
et al. 1996) and by a twofold lower rise in blood glucose in
response to the systemic infusion of glucagon in individuals
carrying the mutation (Tonolo et al. 1997).
Previous studies in the Olivetti cohort (including adult
men workers of the Olivetti Company in southern Italy)
have described that the Gly40Ser mutation of the
glucagon receptor is associated with an increased risk of
hypertension, an enhanced proximal tubular sodium reab-
sorption (Strazzullo et al. 2001) and with anthropometric
indices of central adiposity (Siani et al. 2001).
In the present study, we analyzed data collected in the
Olivetti participants to determine whether the carriers of
the Gly40Ser mutation of the glucagon receptor exhibit an
abnormal potassium handling. We hypothesized that a less
sensitive glucagon receptor in the kidney might lead to a
less efficient secretion of potassium in the collecting duct
and thus, to a less efficient urinary excretion of potassium.
Subjects and Methods
The Olivetti Heart Study is an epidemiological investiga-
tion of cardiovascular risk factors carried out in southern
Italy. The study started in 1975 with periodical follow-up
for 30 years and involved the Olivetti factories male
workforce (Olivetti Heart Study official website: www.
olivettiheartstudy.org). Most of the data presented in the
present article were collected during the 2002–2004 fol-
low-up visit during which a total of 940 men (age range
25–75 years) were examined. The local Ethics Committee
approved the study protocol, and participants provided
informed written consent.
Procedures
A detailed description of the procedures has been
reported in previous papers (Cappuccio et al. 1993;
Strazzullo et al. 2001; Galletti et al. 2007). The partici-
pants underwent anthropometric measurements, fasting
blood tests, a fixed-sequence questionnaire including
demographic information, past medical history, and a
food frequency questionnaire. Body weight and height
were measured and the body mass index (BMI) was cal-
culated as weight (kg) divided by the square of the height
(m). The waist circumference was measured at the
umbilicus level. Systolic and diastolic (phase V) blood
pressure (SBP and DBP, respectively), and heart rate
(HR) were taken three times, 2 min apart, with a random
zero sphygmomanometer (Gelman Hawksley Ltd, Sussex,
UK) and the average of the last two readings was used for
SBP, DBP and HR.
A fasting venous blood sample was taken and the blood
specimens were immediately centrifuged and stored at
70°C until analyzed. A 24-h urine collection was
obtained from each participant, on the day preceding the
visit, for the measurement of sodium, potassium, urea
and creatinine excretion. This urine was delivered to the
laboratory for immediate storage of aliquot samples at
70°C until measurement.
The assessment of the Gly40Ser polymorphism of the
glucagon receptor had been carried out on 971 out of
1075 participants at follow-up visit in 1994–95, as
described previously (Hager et al. 1995). The Gly40Ser
variant was present in 37 subjects (3.8%). There was no
subject homozygote for the mutation. The allele distribu-
tion followed the Hardy–Weinberg equilibrium. Of the
original 971 participants, 812 (84%) were again seen at
2002–04 follow-up examination. For the purpose of this
analysis, a complete database for the serum and urinary
potassium parameters at the 2002–2004 follow-up exami-
nation was available for 25 carriers of the G allele. We
then selected in the same cohort the highest possible
number of age- and weight-matched CC controls for each
of the 25 carriers of the G allele. This resulted in 4 CC
noncarriers for each of the G allele carriers.
Laboratory measurements and calculations
Serum glucose concentration and serum and urinary urea
concentration were measured using an automated analyser
(Cobas-Mira; Roche, Milan, Italy). Serum and urinary cre-
atinine concentration was assessed by the picric acid col-
orimetric method (Jaffe‘s) using a Cobas-Mira analyzer.
Serum and urinary sodium and potassium concentrations
(SNa, UNa, SK, and UK, respectively) were measured by
atomic absorption spectrophotometry. Serum insulin con-
centration was measured by radioimmunoassay (Insulina
Lisophase, Technogenetics, Milan, Italy).
The volume of the previous 24-h urine collection was
measured. Urine osmolarity (Uosm in mosm/L) was
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estimated by the following formula: (UNa + UK) 9
2 + Uurea, where UNa, UK and Uurea are the urinary con-
centrations of sodium, potassium, and urea, respectively,
in mmol/L (Youhanna et al. 2017). Serum osmolarity
(Sosm) was calculated in the same way, with the addition
of serum glucose concentration. The sodium and potas-
sium excretion rates were calculated by multiplying their
respective urinary concentration by the 24-h urine
volume.
The transtubular potassium gradient (TTKG) is an
index used to quantify the intensity of active potassium
secretion in the cortical collecting duct (West et al.
1986a). It is calculated by the formula TTKG = (UK/SK)/
(Uosm/Sosm). It reflects how much potassium is concen-
trated in the urine above its plasma value, in excess of all
osmoles.
Statistical analysis
Results are expressed as means and 95 % confidence
intervals (CI) unless otherwise indicated. Two-sided
P < 0.05 was considered statistically significant. The dis-
tributions of serum glucose and insulin deviated signifi-
cantly from normality. Analysis of variance (ANOVA)
was used to assess differences between group means for
all normally distributed variables. The Mann–Whitney U
test was used to evaluate statistical differences between
groups when the variables were not normally distributed.
Multivariable regression analysis was performed to cal-
culate the TTKG means accounting for possible con-
founding factors, using TTKG as dependent variable and
selected variables as covariates. All statistical analyses were
performed using the Statistical Package for Social Sciences
(SPSS-PC version 11; SPSS Inc., Chicago, IL).
Results
As shown in Table 1, the main characteristics of the 25
carriers and 100 noncarriers of the G variant are very
similar. There was a 20% lower serum insulin concentra-
tion in the carriers than in the noncarriers but this differ-
ence did not reach statistical significance. There was no
difference in type and amount of antihypertensive treat-
ment between groups (Table 2).
Table 3 displays the main results concerning renal
potassium handling according to the glucagon receptor
gene polymorphism. There was no difference in serum
potassium concentration between the two groups. The
mean 24 h potassium excretion rate was also similar in
the two groups. However, the urinary concentration of
potassium, the urine/serum potassium concentration
ratio, and the TTKG were significantly lower by about
20% in the carriers compared to noncarriers. By contrast,
there was no difference in urinary sodium concentration.
The average urine volume tended to be slightly higher
and urine osmolarity slightly lower in the carriers than in
the noncarriers, which may suggest a modest urine con-
centrating defect in the carriers of the mutation.
Multivariate regression analysis was used to assess the
impact of relevant confounders on the TTKG between-
group difference. After adjustment for serum insulin (that
was about 20% lower in the carriers, even if this differ-
ence was not significant, see Table 1) and for 24-h uri-
nary urea and sodium excretion rates (because these
other solutes could influence potassium handling), TTKG
remained significantly lower (by 15 %) in the GC than
in the CC participants (Fig. 1): GC = 4.27 (95%
CI = 3.76–4.79) versus CC = 4.95 (4.70–5.20) (P < 0.02).
This model explains about 7% of the overall TTKG
variance.
Discussion
In this study, to determine if glucagon influences the
renal handling of potassium, we took advantage of a vari-
ant of the glucagon receptor gene that results in a partial
loss of function of the glucagon receptor. We compared
25 heterozygous carriers of the mutation (GC) with 100
Table 1. Characteristics of the subjects according to the glucagon receptor gene polymorphism.
Noncarriers (N = 100) Carriers (N = 25) P
Age (y) 57 (56–59) 57 (54–61) NS
BMI (kg/m2) 28 (27–28) 28 (27–29) NS
Waist circumf. (cm) 98 (97–100) 100 (96–103) NS
SBP (mm Hg) 136 (133–139) 138 (134–143) NS
DBP (mm Hg) 89 (87–91) 90 (87–92) NS
Heart rate (bpm) 67 (66–69) 68 (64–72) NS
Creat.Clear (ml/min 9 1.73 m2) 86 (82–90) 88 (81–95) NS
Serum insulin (mU/L) 9.6 (8.5–10.7) 7.5 (5.9–9.2) NS (P = 0.09) *
Serum glucose (mmol/L) 5.47 (5.24–5.69) 5.48 (4.78–6.17) NS *
Means (95% CI). P from ANOVA for normally distributed variables, and from a Mann–Whitney U test for nonnormally distributed variables (*).
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control subjects without the mutation (CC). The results
did not reveal any between-group difference in serum
potassium concentration in a fasting morning blood sam-
ple but the urinary potassium concentration was lower by
20% in the carriers of the mutation. The TTKG, which
reflects the intensity of potassium secretion in the cortical
collecting duct, was also significantly lower in the carriers
of the mutation, even after adjustment for possible con-
founders. The differences observed cannot be accounted
for by differences in potassium intake because the 24 h
potassium excretion rate, a reliable marker of potassium
intake, was similar in both groups.
Epidemiological associations do not allow establishing
a causality link between two factors. However, when a
phenotypic variable is associated with a genetic alteration
leading to a significant functional change (here, the par-
tial loss of function of the glucagon receptor), it repre-
sents a Mendelian randomization that allows to draw a
causality link between the genotype and the phenotype
(Smith and Ebrahim 2003; Didelez and Sheehan 2007;
Verduijn et al. 2010). Alleles are randomly allocated dur-
ing gamete formation and thus the risk for confounding
of the genetic variant to the outcome association and for
reverse causality is minimized. Thus, the present results
do support a causal role for the altered glucagon receptor
in the abnormal renal potassium handling.
We had previously observed in rats that the infusion of
glucagon increases the excretion of potassium and the
TTKG (Ahloulay et al. 1995). The present results in
humans are in good agreement with the conclusions of
the rat study. Altogether these rat and human results
strongly suggest that glucagon plays a role in potassium
excretion by stimulating potassium secretion in the distal
nephron. The infusion of potassium in conscious dogs
was shown to stimulate simultaneously both insulin and
glucagon secretion (Santeusanio et al. 1973). It is logical
Table 2. Antihypertensive drug consumption among participants according to the glucagon receptor gene polymorphism (in % of all subjects
in each group)
Noncarriers (N = 100) Carriers (N = 25) P
Number of participants treated with antihypertensive drugs 36 (36%) 9 (36%) NS
Mean number of antihypertensive drugs per subject 0.6 0.6 NS
ACE inhibitors (% of subjects) 18.8 16.7 NS
Angiotensin Receptor Blockers (% of subjects) 6.2 11.1 NS
Calcium channel blockers (% of subjects) 14.1 22.2 NS
Beta-blockers (% of subjects) 9.4 0 NS
Alpha-receptor blockers (% of subjects) 0 11.1 NS
Diuretics (% of subjects) 1.6 0 NS
Table 3. Main serum and urine variables according to the glucagon receptor gene polymorphism.
Noncarriers (CC) Carriers (GC) GC/CC P
Serum K conc. (mmol/L) 4.5 (4.4–4.6) 4.5 (4.3–4.6) 1.00 NS
Urine K conc. (mmol/L) 47 (43–51) 38 (34–43) 0.81 P = 0.030
K excretion rate (mmol/d) 68 (64–73) 66 (57–74) 0.97 NS
Urine K / Serum K ratio 10.6 (9.7–11.5) 8.6 (7.6–9.6) 0.81 P = 0.034
FE K (%) 11.7 (10.9–12.4) 10.8 (9.5–12.0) 0.92 NS
TTKG 5.0 (4.7–5.2) 4.2 (3.9–4.6) 0.84 P = 0.015
Serum urea conc. (mmol/L) 6.2 (5.9–6.5) 6.4 (5.8–7.0) 1.03 NS
Urine urea conc. (mmol/d) 394 (370–419) 440 (387–493) 1.11 NS
Serum Na conc (mmol/L) 140 (139–140) 139 (137–140) 0.99 NS
Urine Na conc. (mmol/L) 137 (128–146) 136 (115–156) 0.99 NS
Na excretion rate mmol/d) 202 (189–214) 228 (197–259) 1.13 NS
Serum osmolarity (mosm/L) 299 (298–301) 298 (296–300) 0.99 NS
Urine volume (L/d) 1.56 (1.46–1.66) 1.72 (1.57–1.87) 1.10 NS
Urine osmolarity (mosm/L) 641 (601–681) 608 (544–673) 0.95 NS
Means (95% CI). P from ANOVA (all variables normally distributed)
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to assume that both hormones may contribute to the reg-
ulation of PK in opposite ways, like they do for plasma
glucose. An independent regulation of glycemia and PK
can be achieved in a combinatory mode as explained pre-
viously (Bankir et al. 2016). In the basal state (as seen at
wake-up in early morning) both insulin and glucagon
secretion are low as well as most metabolic and excretory
functions. An acute carbohydrate intake will selectively
increase insulin secretion while a prolonged fast will selec-
tively stimulate glucagon secretion. A meat meal, bringing
significant amounts of potassium along with proteins, will
increase the secretion of both hormones. These combina-
tory changes can account for an independent regulation
of both plasma glucose and plasma potassium concentra-
tions (Bankir et al. 2016).
This study revealed no between-group difference in
serum potassium concentration. But it should be stressed
that the blood sample was taken in the morning after a
usual nighttime fast. Plasma glucagon concentration
(Pglucagon) is low in the early morning and rises after each
meal (as shown in Fig. 1 of (Velho et al. 1996)). Thus,
the early timing of blood collection in this study was not
well suited for revealing a possible defect due to the
mutated receptor because glucagon’s action on its recep-
tors was probably at its lowest level. Apart from the unfa-
vorable timing of blood collection, this study has several
other limitations, including the small number of subjects,
the fact that only men were studied, that only one TTKG
value was available per subject, and that serum (or
plasma) glucagon concentration was not measured. It is
conceivable that glucagon secretion is reset to a higher
level in the carriers of the mutation, thus, possibly attenu-
ating the consequences of the reduced responsiveness
of the receptor. To our knowledge, plasma glucagon
concentration has not been reported in any of the papers
that have studied subjects with this mutation. Aldosterone
was unfortunately not available in this study. But even if
there was a significant difference between the two groups,
it could be interpreted as an adaptative response to the
receptor mutation and its functional consequences,
because of the Mendelian randomization characteristics of
this study (see above).
TTKG has been used in a number of studies in human
subjects to reflect the intensity of potassium secretion in
the cortical collecting duct. It can be used only if urine Na
concentration exceeds 25 mEq/L and urine osmolality
exceed plasma osmolality (Choi and Ziyadeh 2008), thus,
when vasopressin exerts its antidiuretic action. These con-
ditions are obviously met in this study. The usefullness of
TTKG has been documented in several studies in human
subjects (West et al. 1986b; Ethier et al. 1990; Rodriguez-
Soriano et al. 1990; Musso et al. 2006).
It is possible to assume that, after each meal, PK should
remain higher for a longer time in GC than in CC sub-
jects. In this case, we could also expect a larger difference
in the fractional excretion of potassium and in TTKG
between the two groups because PK is one of the elements
of the formulas used to calculate these variables.
Ideally, the comparison of the two groups should be
evaluated by collecting blood and urine after the intake of
a standardized protein meal or an infusion of amino acids
that are known to significantly increase glucagon secretion
(see review in (Bankir et al. 2015)). In order to specifi-
cally investigate the consequences of the glucagon recep-
tor mutation on potassium handling, it would be
appropriate to compare plasma potassium concentration
and TTKG after a standardized oral potassium load in a
“potassium tolerance test” similar to the glucose tolerance
test. Alternatively, or in addition, it would be interesting
to evaluate if subjects treated with selective nonpeptide
glucagon receptor antagonists (Shen et al. 2011; Filipski
2015; Kelly et al. 2015) exhibit a higher and more durable
rise in plasma potassium after each meal. But in most, if
not all studies, blood is taken in the early morning, not
after the meals.
In conclusion, this study, although based on a nonopti-
mal timing of blood sampling, revealed that a partial loss-
of-function mutation of the glucagon receptor leads to a
reduced efficiency of urinary potassium excretion in
humans. The fact that glucagon influences renal potassium
handling suggests that glucagon might play a role in potas-
sium homeostasis, along with insulin, and in addition to
aldosterone. This hypothesis should be further evaluated by
clinical investigations involving a standardized protein
meal (or an amino acid infusion), and/or a potassium load,
comparing plasma potassium and TTKG in subjects with
the mutation and control subjects.
(P < 0.02)
Figure 1. Difference in transtubular potassium gradient between
carriers and noncarriers of the GCGR gene polymorphism after
multivariate regression analysis accounting for serum insulin and
24-h sodium and urea excretion rates.
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